Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 19/20 | 0.66 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4110120 | 0.95 | PRKDC (0.65) | PRKDC | |
| SCHEMBL13403517 | 0.85 | PRKDC (0.78) | PRKDCPIK3CDPIK3CAPIK3CB | |
| SCHEMBL13403506 | 0.84 | PRKDC (0.77) | PRKDCPIK3CDPIK3CAPIK3CB | |
| SCHEMBL13437671 | 0.80 | PRKDC (0.73) | PRKDCPIK3CDPIK3CAPIK3CB | |
| SCHEMBL4109272 | 0.80 | PRKDC (1.00) | PRKDCPIK3CDPIK3CAPIK3CB | |
| SCHEMBL13403505 | 0.80 | PRKDC (0.72) | PRKDCPIK3CDPIK3CAPIK3CB | |
| SCHEMBL3718685 | 0.77 | PRKDC (0.71) | PRKDCPIK3CDPIK3CAPIK3CB | |
| SCHEMBL3715572 | 0.77 | PRKDC (0.70) | PRKDCPIK3CDPIK3CAPIK3CB | |
| SCHEMBL3628127 | 0.76 | PRKDC (0.72) | PRKDCPIK3CAPIK3CB | |
| SCHEMBL3805277 | 0.76 | PRKDC (0.66) | PRKDCPIK3CDPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090035394-A1 | USE OF DNA-PK INHIBITION TO SENSITISE ATM DEFICIENT CANCERS TO DNA-DAMAGING CANCER THERAPIES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-02-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090035394-A1 | USE OF DNA-PK INHIBITION TO SENSITISE ATM DEFICIENT CANCERS TO DNA-DAMAGING CANCER THERAPIES | ATM, CHEK2, DCK | PRKDC 37/4885PIK3CD 816/4885PIK3CA 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.